Kishen Mehta has approximately 18 years of experience in the healthcare industry, including over 15 years dedicated to hedge fund research and 3 years of company advisory experience. Mr. Mehta is the Chief Investment Officer of Averill and Madison. Prior to joining the Firm, Mr. Mehta served as a Strategic Advisor to Biohaven Pharmaceuticals where he advised the firm on various business development, corporate strategy, and capital structure decisions. From 2016 to 2018, Mr. Mehta served as a Portfolio Manager at Surveyor Capital, a division of Citadel, where he managed a beta and factor neutral, healthcare-focused long/short equity portfolio. From 2012 to 2016, he was an Analyst at Adage Capital, where he played an integral role in scaling a public/private portfolio of therapeutics. From 2010-2012, Mr. Mehta was an Analyst at Apothecary Capital, a division of BBT Capital where he worked on a public/private therapeutics portfolio. From 2007-2010, Mr. Mehta worked as a Mergers & Acquisitions Analyst at Evercore Partners, focusing on pharmaceuticals. Mr. Mehta graduated with a BS degree in Finance & Accounting from NYU Stern School of Business in 2007.